Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Viruses with RNA Genomes

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial.

International journal of molecular sciences·2026

Same author

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease.

Gut·2026

Same author

Effect of Glycated Hemoglobin Levels on Serum Mac-2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C-Virus Related Hepatic Fibrosis.

Journal of medical virology·2026

Same author

A Machine Learning Framework for Cancer Prognostics: Integrating Temporal and Immune Gene Dynamics via ARIMA-CNN.

Biomedicines·2025

Same author

Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal of gastroenterology and hepatology·2025

Same author

Hepatitis B core-related antigen kinetics predict spontaneous HBeAg seroclearance in chronic hepatitis B patients.

Journal of gastroenterology·2025

Search research articles

Related Experiment Video

Updated: Mar 28, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Hepatitis B virus: new therapeutic perspectives.

Chih-Lin Lin^1,2, Hung-Chih Yang^3,4,5, Jia-Horng Kao^4,5,6,7

¹Department of Gastroenterology, Ren-Ai branch, Taipei City Hospital, Taipei, Taiwan.

Liver International : Official Journal of the International Association for the Study of the Liver

|January 5, 2016

Summary

New therapies aim to cure chronic hepatitis B virus (HBV) infection by targeting viral replication and host immune responses. These innovative treatments offer hope for eliminating persistent HBV covalently closed circular DNA (cccDNA) and achieving a functional cure.

Keywords:

chronic hepatitis B covalently closed circular DNA hepatitis B virus

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Experiment Videos

Last Updated: Mar 28, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Area of Science:

Hepatology
Virology
Immunology

Background:

Current antiviral therapies like interferon (IFN) and nucleos(t)ide analogues (NAs) improve outcomes for chronic hepatitis B virus (HBV) infection but do not eliminate persistent covalently closed circular DNA (cccDNA).
Persistent cccDNA can lead to viral relapse after discontinuing treatment, highlighting the need for curative strategies.

Purpose of the Study:

To review emerging therapeutic strategies for a potential cure of chronic hepatitis B (CHB).
To discuss novel agents targeting viral and host factors involved in HBV replication and persistence.

Main Methods:

Review of current research on HBV lifecycle and virus-host interactions.
Analysis of novel therapeutic agents including polymerase inhibitors, cccDNA-targeting agents, capsid assembly inhibitors, entry inhibitors, and immunomodulatory therapies.

Main Results:

New polymerase inhibitors (tenofovir alafenamide, besifovir) offer safer treatment options.
Agents targeting cccDNA (engineered nucleases, RNA interference) aim for elimination or transcriptional silencing.
HBV entry inhibitors (Myrcludex-B) reduce cccDNA amplification and intrahepatic spread.
Host-targeting agents (LTβR agonists, TLR agonists, immune checkpoint inhibitors, therapeutic vaccines) aim to enhance immune responses for HBV-infected cell elimination.

Conclusions:

Multiple novel therapeutic approaches are under development to achieve a cure for HBV infection.
These strategies target different aspects of the HBV lifecycle and host response, offering a promising future for HBV eradication.